Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Sunitinib for treating high-risk RCC

Daniel George • 2 Jun 2019
ASCO 2019
Prostate Cancer Sunitinib

Daniel George, MD, of the Duke University Cancer Center, Durham, NC describes the key findings from a recent phase III trial of adjuvant sunitinib in the treatment of renal cell carcinoma at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Daniel George

3:54
Race & prostate cancer: what's the link?
Daniel George • 2 Jun 2019
2:10
Radium-223 in men with bone mCRPC
Daniel George • 2 Jun 2019

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals